AU2006212770B2 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms - Google Patents

Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms Download PDF

Info

Publication number
AU2006212770B2
AU2006212770B2 AU2006212770A AU2006212770A AU2006212770B2 AU 2006212770 B2 AU2006212770 B2 AU 2006212770B2 AU 2006212770 A AU2006212770 A AU 2006212770A AU 2006212770 A AU2006212770 A AU 2006212770A AU 2006212770 B2 AU2006212770 B2 AU 2006212770B2
Authority
AU
Australia
Prior art keywords
cell
cells
sir2
nicotinamide
silyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006212770A
Other languages
English (en)
Other versions
AU2006212770A1 (en
Inventor
Kevin J. Bitterman
David A. Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2006212770A1 publication Critical patent/AU2006212770A1/en
Application granted granted Critical
Publication of AU2006212770B2 publication Critical patent/AU2006212770B2/en
Priority to AU2013206647A priority Critical patent/AU2013206647A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
AU2006212770A 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms Expired AU2006212770B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013206647A AU2013206647A1 (en) 2005-02-08 2013-07-02 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/053,185 US7977049B2 (en) 2002-08-09 2005-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US11/053,185 2005-02-08
PCT/US2006/004397 WO2006086454A2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013206647A Division AU2013206647A1 (en) 2005-02-08 2013-07-02 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Publications (2)

Publication Number Publication Date
AU2006212770A1 AU2006212770A1 (en) 2006-08-17
AU2006212770B2 true AU2006212770B2 (en) 2013-04-04

Family

ID=36591266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006212770A Expired AU2006212770B2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Country Status (7)

Country Link
US (2) US7977049B2 (enExample)
EP (1) EP1851240B1 (enExample)
JP (3) JP2008529502A (enExample)
AU (1) AU2006212770B2 (enExample)
CA (1) CA2595495C (enExample)
ES (1) ES2401342T3 (enExample)
WO (1) WO2006086454A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421269A1 (en) * 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20090117543A1 (en) * 2004-05-04 2009-05-07 President And Fellows Of Harvard College Methods and compositions for inducing sirtuins
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
EP2175026B1 (en) * 2004-09-24 2014-07-30 Bayer CropScience NV Stress resistant plants
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
CA2610854A1 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20090137681A1 (en) * 2005-04-08 2009-05-28 David A Sinclair Sirtuin Inhibiting Compounds
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
CA2646476A1 (en) * 2006-03-21 2007-09-27 Bayer Bioscience N.V. Stress resistant plants
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008095142A1 (en) * 2007-01-31 2008-08-07 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine
US8180580B2 (en) * 2007-02-01 2012-05-15 The Wistar Institute Method for identifying a compound that modulates SIR2 protein activity
US20110082189A1 (en) * 2007-10-23 2011-04-07 President And Fellows Of Harvard College Use of compounds activating sirt-3 for mimicking exercise
EP2222833A4 (en) * 2007-11-30 2011-05-18 Univ California Industrial production of organic compounds using recombinant organisms expressing methyl halide transferase
JP5570731B2 (ja) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 ピロリン酸の測定方法
CA2745376A1 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2010081115A1 (en) 2009-01-09 2010-07-15 University Of Texas Southwestern Medical Center Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2805041A1 (en) 2009-07-22 2011-01-27 The Regents Of The University Of California Cell-based systems for production of methyl formate
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
GB201007197D0 (en) * 2010-04-30 2010-06-16 Ge Healthcare Uk Ltd Methods and kits for determining the toxicity of an agent
JP6126528B2 (ja) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 神経新生促進化合物
WO2012068463A2 (en) * 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
WO2013002879A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
WO2014059031A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
RU2586300C1 (ru) 2012-10-17 2016-06-10 Метилэйшн Сайенсис Интернэшнл Срл Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты
CN109985056A (zh) 2013-10-30 2019-07-09 可劳迈戴斯有限公司 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) * 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US10513706B2 (en) * 2014-04-09 2019-12-24 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US9995758B1 (en) 2014-10-31 2018-06-12 Western Autotroph Company LLC Methods and systems for controlling oxidative stress in humans and animals
JP7236215B2 (ja) 2015-03-09 2023-03-09 ダブリュー・アール・グレース・アンド・カンパニー－コーン ニコチンアミドリボシドの結晶形
CA2984379C (en) 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2016178949A1 (en) * 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving skin health and compositions therefor
EP3288529A1 (en) 2015-05-01 2018-03-07 The Procter and Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
US20160374908A1 (en) 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
EA035664B1 (ru) 2015-08-05 2020-07-23 МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN115414273B (zh) 2016-01-11 2024-01-30 宝洁公司 处理皮肤状况的方法以及用于其的组合物
SG11201808573YA (en) 2016-03-31 2018-10-30 Berkeley Lights Inc Nucleic acid stabilization reagent, kits, and methods of use thereof
AU2017254657A1 (en) * 2016-04-20 2018-11-15 ChromaDex Inc. Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US20190350960A1 (en) 2017-01-04 2019-11-21 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company Composition and method for improving the appearance of skin
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
IL272410B2 (en) 2017-08-03 2025-12-01 Synthorx Inc Cytokine conjugates for the treatment of autoimmune diseases
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
WO2020010036A1 (en) 2018-07-03 2020-01-09 The Procter & Gamble Company Method of treating a skin condition
CN113660946A (zh) 2019-02-06 2021-11-16 新索思股份有限公司 Il-2缀合物及其使用方法
WO2020174492A1 (en) 2019-02-25 2020-09-03 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US20220324899A1 (en) * 2019-08-14 2022-10-13 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
CN111394268B (zh) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 基因工程菌及其构建方法、应用，生产nad+的方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法
CA3188685A1 (en) * 2020-08-07 2022-02-10 Joe G.N. Garcia Single nucleotide polymorphisms and treatment of inflammatory conditions
CN117545488A (zh) 2021-05-27 2024-02-09 麦德龙国际生物科技有限责任公司 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法
WO2023086770A1 (en) * 2021-11-10 2023-05-19 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection gene therapy
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
CN121218887A (zh) 2023-05-15 2025-12-26 博纳菲德健康有限公司 睡眠改善组合物和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179937A (en) 1978-06-02 1979-12-25 Ocean Ecology Ltd. Sound measuring device
FR2543550B1 (fr) 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63152309A (ja) * 1986-08-11 1988-06-24 Lion Corp 皮膚外用剤
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5689046A (en) 1987-09-30 1997-11-18 Bayer Aktiengesellschaft Stilbene synthase gene
DE3733017A1 (de) 1987-09-30 1989-04-13 Bayer Ag Stilbensynthase-gen
JP2736103B2 (ja) * 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE4107396A1 (de) 1990-06-29 1992-01-02 Bayer Ag Stilbensynthase-gene aus weinrebe
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
JP3214049B2 (ja) 1992-03-09 2001-10-02 史衛 佐藤 シス−オレフィンの製造法
DE4232899C2 (de) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
IL107642A0 (en) 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FI951138A7 (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
DE69534166T2 (de) 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
DE4440200A1 (de) 1994-11-10 1996-05-15 Bayer Ag DNA-Sequenzen und ihre Verwendung
AU709498B2 (en) 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
DE4444238A1 (de) 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ATE352634T1 (de) 1995-02-24 2007-02-15 Univ Pennsylvania Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
IT1276225B1 (it) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
FR2741238B1 (fr) 1995-11-17 2001-11-30 Goemar Lab Sa Utilisation du chlorure d'aluminium comme agent eliciteur de la synthese du resveratrol
US6124125A (en) 1996-01-08 2000-09-26 Trustees Of Dartmouth College AMP activated protein kinase
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
FR2766176B1 (fr) 1997-07-15 1999-10-29 Caudalie Compositions a base de derives de resveratrol
US6270780B1 (en) 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
US6537969B1 (en) 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6008260A (en) 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
AT407821B (de) 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6448450B1 (en) 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6197834B1 (en) 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
ATE324105T1 (de) 1998-09-08 2006-05-15 Cornell Res Foundation Inc Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
US6656925B2 (en) 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
IT1302365B1 (it) 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US6361815B1 (en) 1998-12-21 2002-03-26 Pure World Botanicals, Inc. Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
US6190716B1 (en) 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
US6878381B2 (en) 1999-03-22 2005-04-12 Pfizer, Inc Resorcinol composition
ATE365326T1 (de) 1999-04-12 2007-07-15 Sumitomo Chemical Co Verfahren zur analyse der menge an intraabdominalem fettgewebe
FR2795643B1 (fr) 1999-07-02 2004-06-11 Oreal Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique
AU765724B2 (en) 1999-08-13 2003-09-25 University Of Maryland Biotechnology Institute Compositions for treating viral infections, and methods therefor
CN1399549A (zh) 1999-09-03 2003-02-26 希格马托健康科学股份公司 超细l－肉碱、其制备方法、含有它的组合物及其使用方法
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6358517B1 (en) 1999-10-22 2002-03-19 Unilever Home & Personal Care Usa, Division Of Conopco Cosmetic compositions containing resveratrol and retinoids
US20020002200A1 (en) 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6416806B1 (en) 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
US20010039296A1 (en) 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
IT1317034B1 (it) 2000-05-30 2003-05-26 Istituto Di Medicina Speriment Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
ITNA20000036A1 (it) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se Nuovi approcci terapeutici per il trattamento della forfora.
ITNA20000037A1 (it) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se Filtro solare multifunzione innovativo.
IT1318565B1 (it) 2000-06-09 2003-08-27 World Pharma Tech Ltd Integratore alimentare proenergetico a base di nadh octocosanolo evitamina e.
US6795856B1 (en) 2000-06-28 2004-09-21 Accountability International, Inc. System and method for monitoring the internet access of a computer
US6319523B1 (en) 2000-06-29 2001-11-20 James H. Zhou Composition and method for inhibiting oral bacteria
US20020120008A1 (en) 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US6812248B2 (en) 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
DE10034320A1 (de) 2000-07-14 2002-02-07 Inst Pflanzenbiochemie Ipb Verfahren zur Beeinflussung des Sinapingehalts in transgenen Pflanzenzellen und Pflanzen
FR2812195B1 (fr) 2000-07-28 2003-07-11 Oreal Compositions a application topique comprenant des hydroxystilbenes glucosyles et utilations
US20020110604A1 (en) 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US6410596B1 (en) 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US6541522B2 (en) 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US6552085B2 (en) 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
AU2002236438A1 (en) 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
CA2431196C (en) 2000-11-15 2012-01-24 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US20030165854A1 (en) 2000-12-05 2003-09-04 Cunningham Mary Jane Marker genes responding to treatment with toxins
US20030082647A1 (en) 2000-12-12 2003-05-01 Reenan Robert A. Transporter protein
US20040005574A1 (en) 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20030191064A1 (en) 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
FR2820320B1 (fr) 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
US20030190381A1 (en) 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
CA2439109A1 (en) 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
ITPI20010014A1 (it) 2001-03-05 2002-09-05 Ivo Pera Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US20030044946A1 (en) 2001-04-03 2003-03-06 Longo Valter D. Genes, mutations, and drugs that increase cellular resistance to damage and extend longevity in organisms from yeast to humans
US6387416B1 (en) 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US20030180719A1 (en) 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
US20030004142A1 (en) 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
WO2002085327A2 (en) 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6426061B1 (en) 2001-04-20 2002-07-30 Weiwei Li Method and composition for preventing sweat-related odor
EP1390026B1 (en) 2001-05-03 2010-05-05 Cornell Research Foundation, Inc. Treatment of hpv caused diseases
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US7199227B2 (en) 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
CN1398838A (zh) 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 二苯乙烯类化合物制备以及它们在治疗和预防糖尿病中的应用
US20030044474A1 (en) 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
US7396546B2 (en) 2001-08-06 2008-07-08 The Quigley Corporation Anti-microbial compositions and methods of using same
WO2003016573A1 (en) 2001-08-15 2003-02-27 Elixir Pharmaceuticals, Inc. Age-associated markers
WO2003024391A2 (en) 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
US6656969B2 (en) 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6680342B2 (en) 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030054053A1 (en) 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030055114A1 (en) 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
MXPA04002621A (es) 2001-09-21 2004-07-08 Univ Tulane Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos.
US20030082116A1 (en) 2001-09-28 2003-05-01 Closure Medical Corporation Adhesive compositions containing dual function stabilizers and active agents
US7119110B2 (en) 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
EP1304161B1 (en) 2001-10-19 2007-02-28 Pacific Corporation Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
DE60105820D1 (de) 2001-10-22 2004-10-28 Pera Ivo E Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit
US6767563B2 (en) 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
AU2002356992A1 (en) 2001-11-21 2003-06-10 Albert Einstein College Of Medicine Of Yeshiva University Sir2 products and activities
US6544564B1 (en) 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition
FR2832630B1 (fr) 2001-11-28 2005-01-14 Oreal Composition cosmetique et/ou dermatologique contenant au moins un actif hydrophile sensible a l'oxydation stabilise par au moins un copolymere de n-vinylimidazole
US20030118617A1 (en) 2001-12-21 2003-06-26 Avon Products, Inc. Resveratrol analogues
NZ516366A (en) 2001-12-24 2004-07-30 Enzo Nutraceuticals Ltd Increased lifespan formulation using pine bark flavonoid extract
AU2002367363A1 (en) 2001-12-26 2003-07-24 The Regents Of The University Of California System and method for identifying networks of ternary relationships in complex data systems
AU2003210477A1 (en) 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
WO2003077901A1 (en) 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20030199581A1 (en) 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
WO2003082887A1 (en) 2002-03-28 2003-10-09 Council Of Scientific And Industrial Research 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, process of isolation from pterocarpus marsupium and pharmaceutical composition for the treatment of diabetes
US20030224077A1 (en) 2002-04-08 2003-12-04 Societe L'oreal S.A. Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
WO2003090681A2 (en) 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
WO2003094833A2 (en) 2002-05-10 2003-11-20 Orchid Chemicals & Pharmaceuticals Limited A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene
US7531337B2 (en) 2002-06-07 2009-05-12 Wisconsin Alumni Research Foundation Method of controlling acetylation of metabolic enzymes
EP1549301A2 (en) 2002-06-10 2005-07-06 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
DE10230961A1 (de) 2002-07-10 2004-02-12 Lorenz, Peter, Dr. Verwendung von Oxyresveratrol als Neuroprotektivum
CA2492248A1 (en) * 2002-07-11 2004-01-22 Avikam Harel Composition and methods for the treatment of skin disorders
WO2004009539A2 (en) 2002-07-19 2004-01-29 Orchid Chemicals And Pharmaceuticals Limited Method for the conversion of a z-isomer into e-isomer
DE10244282A1 (de) 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
JP5335192B2 (ja) 2003-05-27 2013-11-06 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助食品組成物及びその使用
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050004052A1 (en) * 2003-07-03 2005-01-06 Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
US20050136429A1 (en) 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US20050038125A1 (en) 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
US20050049208A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
EP1677794B1 (en) 2003-09-12 2014-12-03 Elixir Pharmaceuticals, Inc. Methods of treating disorder
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
ATE389478T1 (de) * 2004-06-03 2008-04-15 Balcke Duerr Gmbh Hydraulisches aufweitverfahren und vorrichtung dafür
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
EP2175026B1 (en) 2004-09-24 2014-07-30 Bayer CropScience NV Stress resistant plants
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
CA2646476A1 (en) 2006-03-21 2007-09-27 Bayer Bioscience N.V. Stress resistant plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Also Published As

Publication number Publication date
CA2595495C (en) 2014-12-09
ES2401342T3 (es) 2013-04-18
JP2008529502A (ja) 2008-08-07
US20120022013A1 (en) 2012-01-26
EP1851240A2 (en) 2007-11-07
CA2595495A1 (en) 2006-08-17
EP1851240B1 (en) 2012-12-12
US20050267023A1 (en) 2005-12-01
JP2012176962A (ja) 2012-09-13
US7977049B2 (en) 2011-07-12
AU2006212770A1 (en) 2006-08-17
JP2015180657A (ja) 2015-10-15
WO2006086454A2 (en) 2006-08-17
WO2006086454A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
AU2006212770B2 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2010219395B2 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
Nezich et al. MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5
Satyanarayana et al. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
AU699969B2 (en) Isolated p27 protein and its encoding nucleic acid molecules
Hu et al. 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling
US8546074B2 (en) Sir2 activity
Mitchell et al. Inositol polyphosphate 5‐phosphatases: lipid phosphatases with flair
US6635450B1 (en) Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents
AU2002320325A1 (en) SIR2 activity
EP1529115A2 (en) Sir2 activity
US6355774B1 (en) Isolated p27 protein
US6242575B1 (en) Antibodies for detecting p27 protein
AU2013206647A1 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
Ibarra-Sánchez Biochemical and cellular function of t-cell protein tyrosine phosphatase
Dimopoulos A Role for Glycogen Synthase Kinase 3 beta in the Regulation of Glucagon Gene Transcription by Insulin
US20020110886A1 (en) Isolated p27 protein and methods for its production and use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)